Format

Send to

Choose Destination
See comment in PubMed Commons below
Vaccine. 2012 May 30;30 Suppl 2:B78-86. doi: 10.1016/j.vaccine.2011.12.099.

Future challenges in the elimination of bacterial meningitis.

Author information

1
Novartis Vaccines & Diagnostics srl, Via Fiorentina 1, 53100 Siena, Italy.

Abstract

Despite the widespread implementation of several effective vaccines over the past few decades, bacterial meningitis caused by Streptococcus pneumoniae, Haemophilus influenzae, Neisseria meningitidis and Group B Streptococcus (GBS) still results in unacceptably high levels of human mortality and morbidity. A residual disease burden due to bacterial meningitis is also apparent due to a number of persistent or emerging pathogens, including Mycobacterium tuberculosis, Escherichia coli, Staphylococcus aureus, Salmonella spp. and Streptococcus suis. Here, we review the current status of bacterial meningitis caused by these pathogens, highlighting how past and present vaccination programs have attempted to counter these pathogens. We discuss how improved pathogen surveillance, implementation of current vaccines, and development of novel vaccines may be expected to further reduce bacterial meningitis and related diseases in the future.

PMID:
22607903
DOI:
10.1016/j.vaccine.2011.12.099
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center